New classification for identifying HR myeloma based on cytogenetic abnormalities

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Revolutionising myeloma treatment through immune profiling

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Guiding transplant decisions in multiple myeloma with MRD

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Post-diagnosis diet, nutrition and cancer prognosis

ESMO and WCLC: Latest developments in EGFR mutated NSCLC